Cannabidiol and the shifting perspective of epilepsy drug discovery Cannabidiol Medicine Research Anticonvulsant Cannabis DrugDiscovery Epilepsy Neurology UW
By Dr. Chinta SidharthanNov 29 2022Reviewed by Benedette Cuffari, M.Sc. In a recent review published in the journal Experimental Neurology, researchers discuss the important clinical and preclinical research conducted during the 20th century that contributed to considering cannabidiol, whose use has been historically regulated or restricted, as a potential antiseizure medication in the 21st century.
Cannabidiol, a phytocannabinoid derived from Cannabis sativa that does not cause withdrawal or euphoria, was approved in 2018 as a treatment for Dravet syndrome , Tuberous Sclerosis Complex , and Lennox‐Gastaut syndrome . However, before cannabidiol was approved by the United States Food and Drug Administration , very few studies had explored its therapeutic potential against epilepsy and seizures due to the regulatory rules and social stigma associated with marijuana derivatives.
Molecular targets being explored for the modulation of excitatory and inhibitory pathways include allosteric modulators of presynaptic sites such as neuronal potassium channels and type 2 metabotropic glutamate receptors. Research on cannabidiol treatment Early research on the medicinal properties of Δ9-tetrahydrocannabinol and cannabidiol, despite not being extensive, revealed that cannabidiol had potential anticonvulsant properties without the euphorigenic activity of THC. Furthermore, maximal electroshock test experiments using animal models showed that cannabidiol had potential applications in cortical focal, grand mal, and complex partial seizure types of epilepsy.
DS is a pediatric disease characterized by developmental epileptic encephalopathy resulting in spontaneous and recurrent seizures and a high incidence of death. This condition is also resistant to traditional antiseizure medications such as carbamazepine and phenytoin.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Phase IIb Randomized, Placebo-Controlled, Dose-Escalating, Double-Blind Study of Cannabidiol Oil for the Relief of Symptoms in Advanced Cancer (MedCan1-CBD) | Journal of Clinical OncologyPURPOSE To determine whether cannabidiol (CBD) oil can improve symptom distress in patients with advanced cancer receiving palliative care. METHODS Participants were adults with advanced cancer and symptom distress (Edmonton Symptom Assessment Scale [ESAS] total score of ≥ 10/90) who received titrated CBD oil 100 mg/mL, 0.5 mL once daily to 2 mL three times a day, or matched placebo for 28 days. The primary outcome was ESAS total symptom distress score (TSDS) at day 14. Response was defined as a decrease in TSDS by ≥ 6 at day 14. Secondary outcomes were ESAS TSDS over time, individual symptom scores, patient-determined effective dose, opioid use, Global Impression of Change, depression, anxiety, quality of life, and adverse events. RESULTS Of the 144 patients randomly assigned, the planned sample size of 58 participants on CBD and 63 on placebo reached the primary analysis point (day 14). The unadjusted change in TSDS from baseline to day 14 was –6.2 (standard deviation, 14.5) for placebo and –3.0 (standard deviation, 15.2) for CBD with no significant difference between arms (P=.24). Similarly, there was no detected difference in proportion of responders (placebo: 37 of 63 [58.7%], CBD: 26 of 58 [44.8%], P=.13). All components of ESAS improved (fell) over time with no difference between arms. The median dose of participant-selected CBD was 400 mg per day with no correlation with opioid dose. There was no detectable effect of CBD on quality of life, depression, or anxiety. Adverse events did not differ significantly between arms apart from dyspnea that was more common with CBD. Most participants reported feeling better or much better at days 14 (53% CBD and 65% placebo) and 28 (70% CBD and 64% placebo). CONCLUSION CBD oil did not add value to the reduction in symptom distress provided by specialist palliative care alone.
Read more »
Researchers use a comparative study to model RSV prevention in childrenUsing computational modeling, a new paper compares the benefit of maternal vaccines versus the administration of respiratory syncytial virus (RSV)-specific monoclonal antibody (mAb) therapy against RSV.
Read more »
Twitter search spam campaign hides China riots, researchers sayElon Musk meanwhile muses whether Apple 'hate[s] free speech in America' because the company mostly stopped advertising on Twitter
Read more »
Researchers propose the tools and frameworks of EBM+ to help overcome the COVID-19 pandemicResearchers propose the tools and frameworks of EBM+ to help overcome the COVID-19 pandemic bmj_company UniofOxford UofT UNSW COVID19 coronavirus covid pandemic medicine evidencebasedmedicine
Read more »
Impact of an individually tailored educational application on vaccine attitudes of pregnant women and mothersImpact of an individually tailored educational application on vaccine attitudes of pregnant women and mothers BMC_series JohnsHopkinsSPH YaleMed YaleSPH CUAnschutz vaccine pregnant vaccination pregnancy app
Read more »